Treatment With DMARDs Does Not Alter COVID-19 Susceptibility and Severity
Researchers evaluated the risk for COVID-19 infection and its severity in patients receiving DMARDs.
All articles by Morgan E. Meissner
Enthesitis Associated With Worse Disease Activity and Quality of Life in Psoriatic Arthritis
Researchers assessed the effect of clinical enthesitis in patients with psoriatic arthritis.
Novel Score May Be a Reliable Tool for the Identification of Dactylitis in Psoriatic Arthritis
Researchers assessed the reliability of a novel score to identify the characteristic lesions of dactylitis in psoriatic arthritis.
Hand Osteoarthritis Associated With Changes in Bone Architecture and Strength
Researchers assessed the impact of primary hand osteoarthritis on bone mass, microstructure, and biomechanics in the affected skeletal regions.
Inclusion of Non-Criteria Features to SLE Classification Improves Diagnostic Accuracy
Researchers identified criteria and non-criteria features associated with SLE, which can be used in classification criteria.
Identification of Distinct Trajectories Based on Pain and Physical Function in Knee and Hip Osteoarthritis
Researchers identified an association between distinct trajectories of pain and physical function and knee and hip osteoarthritis.
Steroid Injections Improve Pain and Functionality Measures in Hand Psoriatic Dactylitis
Researchers assessed the effectiveness of steroid injections vs systemic treatment on dactylitis in patients with psoriatic arthritis.
Updated AACE/ACE Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis: What Do Clinicians Need to Know?
The ACE and AACE released a 2020 update to their clinical practice guidelines for the treatment and diagnosis of postmenopausal osteoporosis.
Comparative Effects of csDMARDs on Stroke and Myocardial Infarction Risk in Rheumatoid Arthritis
Researchers quantified the comparative effect of csDMARDs on the risk for myocardial infarction and stroke in rheumatoid arthritis.
Safety and Efficacy of Romosozumab Demonstrated in Postmenopausal Women With Mild to Moderate CKD
The safety and efficacy of romosozumab for osteoporosis treatment in postmenopausal women are not significantly affected by reduced kidney function.
-
Loading...
-
Loading...
Next post in EULAR 2020 Coverage
